Atenolol 50 mg Amlodipine 5 mg Tablet

Overdosage may cause hypotension and less commonly, congestive cardiac failure. Unabsorbed drug may be removed by gastric lavage or use of activated charcoal. Symptomatic treatment may be administered.Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.

Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.

Combination of the two drugs results in additive antihypertensive action.
Absorption: Amlodipine: Plasma levels peak 6-12 hr after oral admin; absolute bioavailability is estimated to be 64-90%. Atenolol:
Absorption is rapid and consistent but incomplete; about 50% of an oral dose is absorbed in the GI tract; plasma levels peak 2-4 hr after oral admin.
Distribution: Amlodipine: 93% bound to plasma proteins. Atenolol: 6-16% bound to plasma proteins.
Metabolism: Amlodipine: About 90% converted to inactive metabolites hepatically. Atenolol: Little or no hepatic metabolism.
Excretion: Amlodipine: 10% of parent compound and 60% of the metabolites are removed in the urine;
elimination from the plasma is biphasic with terminal half-life of about 30-50 hr. Atenolol: 50% of the oral dose is removed unchanged in the faeces; absorbed drug is removed mainly via renal elimination; half-life is about 6-7 hour.